CytoDyn received clearance from Brazil’s FDA (ANVISA) to commence pivotal phase 3 trial in critically ill COVID-19 patients
| | | |

CytoDyn received clearance from Brazil’s FDA (ANVISA) to commence pivotal phase 3 trial in critically ill COVID-19 patients

On Aug. 3, 2021, CytoDyn announced that Brazilā€™s regulatory authority ANVISA (AgĆŖncia Nacional de VigilĆ¢ncia SanitĆ”ria) has approved…